Tag: NIH
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Featured Article
Manufacturers should do this sooner rather than later, says precision engineer
Australian precision engineering and industrial instrumentation company CENMAC implemented ERP software when it was still a one-man operation. “I couldn’t imagine us growing to this size without MRPeasy,” says Jason Ford, Founder.
